The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome
Open accessAbstract
This study examines the clinical impact of PTEN genomic deletions using fluorescence in situ hybridisation (FISH) analysis of 107 prostate cancers, with follow-up information covering a period of up to 10 years. Tissue microarray analysis using interphase FISH indicated that hemizygous PTEN losses were present in 42/107 (39%) of prostatic adenocarcinomas, with a homozygous PTEN deletion observed in 5/107 (5%) tumours. FISH analysis using closely linked probes centromeric and telomeric to the PTEN indicated that subband microdeletions accounted for approximately 70% genomic losses. Kaplan-Meier survival analysis of PTEN genomic losses (hemizygous and homozygous deletion vs not deleted) identified subgroups with different prognosis based on their time to biochemical relapse after surgery, and demonstrated significant association between PTEN deletion and an earlier onset of disease recurrence (as determined by prostate-specific antigen levels). Homozygous PTEN deletion was associated with a much earlier onset of biochemical recurrence (P=0.002). Furthermore, PTEN loss at the time of prostatectomy correlated with clinical parameters of more advanced disease, such as extraprostatic extension and seminal vesicle invasion. Collectively, our data indicates that haploinsufficiency or PTEN genomic loss is an indicator of more advanced disease at surgery, and is predictive of a shorter time to biochemical recurrence of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.2.106 · Cited by 5,314
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484 · cited 1×
“Previous cytogenetic and genomic profiling analyses have identified several tumour-associated chromosomal rearrangements in the initial stages of sporadic primary prostate cancer, consisting predominantly of losses (Visakorpi et al, 1995; Verhagen et al, 2000; Elo and Visakorpi, 2001).”
BackgroundMajumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
McMenamin, M. E., Soung, P., Perera, S., Kaplan, I. D., Loda, M. F., & Sellers, W. R. (1999) · PubMed · Cited by 640
Whang, Y. E., Wu, X., Suzuki, H., Reiter, R. E., Tran, C., Vessella, R. L., Said, J. W., Isaacs, W. B., & Sawyers, C. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5246 · Cited by 639
TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer
Perner, S., Demichelis, F., Beroukhim, R., Schmidt, F. H., Mosquera, J.-M., Setlur, S., Tchinda, J., Tomlins, S. A., Hofer, M. D., Pienta, K. G., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1482 · Cited by 502
Gene expression profiling predicts clinical outcome of prostate cancer
Glinsky, G. V., Glinskii, A. B., Stephenson, A. J., Hoffman, R. M., & Gerald, W. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20032 · Cited by 479
Pathological and molecular aspects of prostate cancer
DeMarzo, A. M., Nelson, W. G., Isaacs, W. B., & Epstein, J. I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12779-1 · Cited by 472
TMPRSS2:ETV4 Gene Fusions Define a Third Molecular Subtype of Prostate Cancer
Tomlins, S. A., Mehra, R., Rhodes, D. R., Smith, L. R., Roulston, D., Helgeson, B. E., Cao, X., Wei, J. T., Rubin, M. A., Shah, R. B., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0168 · Cited by 469
Wang, J., Cai, Y., Ren, C., & Ittmann, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1966 · Cited by 404
Graff, J. R., Konicek, B. W., McNulty, A. M., Wang, Z., Houck, K., Allen, S., Paul, J. D., Hbaiu, A., Goode, R. G., Sandusky, G. E., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003145200 · Cited by 378
Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression
Kwabi-Addo, B., Giri, D., Schmidt, K., Podsypanina, K., Parsons, R., Greenberg, N., & Ittmann, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201167798 · Cited by 323
Ventura, R., Martín-Subero, J. I., Jones, M., McParland, J., Gesk, S., Mason, D. Y., & Siebert, R. (2006) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2006.050083 · Cited by 303
Cerveira, N., Ribeiro, F. R., Peixoto, A., Costa, V., Henrique, R., Jerönimo, C., & Teixeira, M. R. (2006) · Neoplasia · doi:10.1593/neo.06427 · Cited by 258
Phosphorylation of HDM2 by Akt
Ashcroft, M., Ludwig, R. L., Woods, D. B., Copeland, T. D., Weber, H. O., MacRae, E. J., & Vousden, K. H. (2002) · Oncogene · doi:10.1038/sj.onc.1205276 · Cited by 197
Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer
Soller, M. J., Isaksson, M., Elfving, P., Soller, W., Lundgren, R., & Panagopoulos, I. (2006) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20329 · Cited by 195
Yoshimoto, M., Joshua, A. M., Chilton-MacNeill, S., Bayani, J., Selvarajah, S., Evans, A. J., Zielenska, M., & Squire, J. A. (2006) · Neoplasia · doi:10.1593/neo.06283 · Cited by 185
Self-citationYoshimoto, M., Cutz, J.-C., Nuin, P. A. S., Joshua, A. M., Bayani, J., Evans, A. J., Zielenska, M., & Squire, J. A. (2006) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2006.04.003 · Cited by 181
Self-citationBaker, S. J. (2007) · Cell · doi:10.1016/j.cell.2006.12.023 · Cited by 171
Wolf, M., Mousses, S., Hautaniemi, S., et al. (2004) · Neoplasia · doi:10.1593/neo.3439 · Cited by 131
PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis
Besson, A., Robbins, S. M., & Yong, V. W. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00542.x · Cited by 130
Molecular genetics of prostate cancer
Elo, J. P., & Visakorpi, T. (2001) · Annals of Medicine · doi:10.3109/07853890109002068 · Cited by 127
Schmitz, M., Grignard, G., Margue, C., Dippel, W., Capesius, C., Mossong, J., Nathan, M., Giacchi, S., Scheiden, R., & Kieffer, N. (2006) · International Journal of Cancer · doi:10.1002/ijc.22359 · Cited by 126
PTEN: tumour suppressor, multifunctional growth regulator and more
Goberdhan, D. C. I., & WILSON, C. G. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg288 · Cited by 121
Verhagen, P. C. M. S., van Duijn, P. W., Hermans, K., Looijenga, L. H. J., van Gurp, R., Stoop, H., van der Kwast, T., & Trapman, J. (2006) · The Journal of Pathology · doi:10.1002/path.1929 · Cited by 108
Ohigashi, T., Mizuno, R., Nakashima, J., Marumo, K., & Murai, M. (2004) · The Prostate · doi:10.1002/pros.20117 · Cited by 93
Loss of PTEN is associated with progression to androgen independence
Bertram, J., Peacock, J. W., Fazli, L., Mui, A., Chung, S. W., Cox, M., Monia, B. P., Gleave, M. E., & Ong, C. J. (2006) · The Prostate · doi:10.1002/pros.20411 · Cited by 81
Characterization of centromere alterations in liposarcomas
Sirvent, N., Forus, A., Lescaut, W., Burel‐Vandenbos, F., Benzaken, S., Chazal, M., Bourgeon, A., Vermeesch, J. R., Myklebost, O., Turc‐Carel, C., et al. (2000) · Genes Chromosomes and Cancer · Cited by 75
Liu, W., Chang, B., Sauvageot, J., Dimitrov, L. M., Gielzak, M., Li, T., Yan, G., Sun, J., Sun, J., Adams, T. S., et al. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20369 · Cited by 72
Chromosomal changes during development and progression of prostate adenocarcinomas
Zitzelsberger, H. F., Engert, D., Walch, A. K., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1533 · Cited by 70
Detection of genetic alterations in advanced prostate cancer by comparative genomic hybridization
Kasahara, K., Taguchi, T., Yamasaki, I., Kamada, M., Yuri, K., & Shuin, T. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(02)00552-6 · Cited by 68
Köksal, İ. T., Dirice, E., Yasar, D., Şanlioğlu, A. D., Çiftçioğlu, A., Gülkesen, K. H., Özeş, N. O., Baykara, M., Lüleci, G., & Şanlıoğlu, S. (2004) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2004.01.009 · Cited by 60
Mezzelani, A., Alasio, L. M., Bartoli, C., Bonora, M. G., Pierotti, M. A., Rilke, F. O., & Pilotti, S. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690387 · Cited by 57
Hughes, S., Yoshimoto, M., Beheshti, B., Houlston, R. S., Squire, J. A., & Evans, A. J. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-65 · Cited by 34
Self-citationETS-TMPRSS2 fusion gene products in prostate cancer
Ahlers, C. M., & Figg, W. D. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.3.2603 · Cited by 16
Cited by
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 801
Clinical implications of PTEN loss in prostate cancer
Jamaspishvili, T., Berman, D. M., Ross, A. E., Scher, H. I., De Marzo, A. M., Squire, J. A., & Lotan, T. L. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.9 · Cited by 651
Self-citationChapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
(2009) · Advances in Cancer Research · doi:10.1016/s0065-230x(09)02002-8 · Cited by 620
“In addition, the decreasing levels of PTEN expression are correlated with the progressive outcome of solid cancers, including ovarian, prostate, and cervical cancers (Harima et al., 2001; Yoshimoto et al., 2007).”
BackgroundTargeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
Sarker, D., Reid, A. H. M., Yap, T. A., & de Bono, J. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0125 · Cited by 366
Lotan, T. L., Gurel, B., Sutcliffe, S., Esopi, D., Liu, W., Xu, J., Hicks, J. L., Park, B. H., Humphreys, E., Partin, A. W., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1244 · Cited by 348
Metadata
- Authors
- Yoshimoto, M., Cunha, I. W., Coudry, R. A., Fonseca, F. P., Torres, C. H., Soares, F. A., & Squire, J. A.
- Venue
- British Journal of Cancer
- Published
- 2007-08
- Volume
- 97
- Issue
- 5
- Pages
- 678-685
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1971081363
- Cited by
- 295
- References
- 39
- FWCI
- 9.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.